Screening for Familial Gastric Cancer in First Degree Relatives

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine whether staining of the gastric mucosa increases the number of detected (pre)malignant foci of intestinal and diffuse type gastric cancer, in first degree relatives of individuals with familial gastric cancer.

Clinical Trial Description

Rationale:

Familial gastric cancer (FGC) concerns about 10% of all gastric cancers. It has an impressive impact on both emotional and physical wellbeing of first degree relatives of patients with (early) onset of gastric cancer. FGC can in 1-3% be attributed to one single hereditary syndrome, the hereditary diffuse gastric cancer (HDGC). HDGC is associated with a CDH1 mutation in about 40 % of the cases. In case there is no CDH1 mutation, referred to as familiar diffuse gastric cancer (FDGC), it remains uncertain how to guide and/or screen family members. The same applies for the rare familial intestinal type gastric cancer (FIGC).

Aim:

In this study we want to determine the value of endoscopic screening in members of families with FGC, both FDGC and FIGC. Also, we will analyze the associations of life style factors, including dietary habits with the development of FDGC, to be able to built preventive strategies. Finally, we want to assess the psychological impact of our screening protocol.

Objective:

Primary, to determine whether staining of the gastric mucosa increases the number of detected (pre)malignant foci of diffuse type gastric cancer, in individuals from families with FDGC as well as dysplastic, adenomatous and early intestinal cancers in individuals from families with FIGC. Secondary: A To determine the optimal pathological work-up the detection rate of (pre-)malignancy. B To determine clinical and life style factors that are associated with the two types of FGC. C To determine the psychosocial impact of the screening protocol in this population. D To develop a strategy for screening individuals from FGC families and creative advise for preventive measures.

Study design:

A randomized controlled trial included in a prospective cohort analysis.

Study population:

All (first degree) relatives , from 18 years and older from patients who fulfill the criteria for a FGC. These are; 1] all first degree relatives of an individual with diffuse gastric cancer, without proven CDH1 mutation, or members from families with 2] 2 or more individuals with gastric carcinoma, at least one < 50 yrs, or 3] 3 or more individuals with gastric carcinoma, any age, any type, or 4] 1 individual with any type gastric carcinoma < 40 yrs. ;

Study Design

Related Conditions & MeSH terms

Adenocarcinoma
Carcinoma, Diffuse Type
Intestinal Type Adenocarcinoma of Stomach
Malignant Neoplasm of Stomach
Neoplasms
Relative (Related Person)
Stomach Neoplasms

Clinical Trial Details

NCT number	NCT01727908
Study type	Interventional
Source	Radboud University
Contact
Status	Terminated
Phase	N/A
Start date	November 2012
Completion date	September 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02337673` - Screening of Postoperative Pulmonary Complications by Electrical Impedance Tomography
Completed	`NCT02158988` - Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis	Phase 3
Recruiting	`NCT01642953` - Early Recovery After Gastric Cancer Surgery	Phase 2
Active, not recruiting	`NCT02205047` - Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2
Recruiting	`NCT02381847` - Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients	Phase 3
Completed	`NCT01443065` - MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma	Phase 2
Completed	`NCT01758965` - Surgicel® Fibrillar for Delayed Bleeding After ESD	N/A
Completed	`NCT02528110` - Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer	Phase 2
Completed	`NCT01187212` - Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE	Phase 2
Recruiting	`NCT05880667` - Adaptive Radiation for Abdominopelvic Metastases	Phase 1
Recruiting	`NCT04345770` - Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Screening for Familial Gastric Cancer in First Degree Relatives — FamGaCan

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms